Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash
Prelude Therapeutics (PRLD) reported Q2 2026 revenue of $5.7M and a net loss of $13.9M, or $0.14 per share. The company said it had $155.2M in cash and marketable securities as of June 30, 2026, projecting a runway into Q2 2028. R&D and G&A fell year over year. It also updated Phase 1 timelines for PRT13722 and PRT12396.
How this was made
The 30-second read
Why it matters
The combination of quarterly cash runway into Q2 2028 and concrete regulatory/clinical progress (IND cleared, Phase 1 enrollment ongoing, Phase 1 initiation planned) can affect valuation via probability-of-success and financing runway assumptions.
Market read
Traders can reassess near-term biotech risk using the new cash runway and the latest IND/Phase 1 execution timeline details.
What to watch
Investors may discount the pipeline milestones if the Phase 1 endpoints, patient recruitment pace, or IND clearance conditions are not detailed in this summary.
Background
Prelude Therapeutics is a clinical-stage biotech with multiple degrader programs; this update covers Q2 2026 financials and several pipeline execution items.
Ticker impact
Prelude Therapeutics reported Q2 2026 revenue of $5.7M, net loss of $13.9M, and $155.2M cash, plus Phase 1 and IND updates.
Likely modest, two-sided reaction unless investors focus on IND clearance and Phase 1 timing versus continued losses.
The article provides fresh quarterly financials and specific pipeline progress (IND cleared, Phase 1 enrollment ongoing, Phase 1 initiation planned), but no explicit guidance beat/miss or capital raise details.
Market effects
Biotech investors may reprice KAT6A degrader and JAK2V617F inhibitor development risk based on IND clearance and Phase 1 enrollment progress.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the update is company-specific and not tied to global regulatory or macro events.
Counterpoint
The cash figure and runway may not reduce dilution risk if trial timelines slip or enrollment costs rise, so the stock may still trade primarily on financing expectations.
Key entities
- companyPrelude Therapeutics
Reported Q2 2026 revenue, net loss, cash runway into Q2 2028, and provided pipeline/regulatory updates across multiple programs.
- drug_programPRT12396
Mutant-selective JAK2V617F inhibitor; IND cleared by FDA and Phase 1 enrollment ongoing for polycythemia vera and myelofibrosis.
- drug_programPRT13722
Oral selective KAT6A degrader; expects to initiate Phase 1 in HR+ breast cancer in Q4 2026 pending IND clearance.
- executiveCharles Morris, M.D.
Appointed Chief Medical Officer in April 2026.
